<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://aminowire.news/news/2026/11/boehringer-survodutide-synchronize-cvot-aha-2026/</loc>
    <news:news>
      <news:publication><news:name>Amino Wire</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-11-09T20:08:23.000Z</news:publication_date>
      <news:title>Survodutide meets CV safety bar in Phase 3 obesity trial</news:title>
    </news:news>
    <image:image><image:loc>https://aminowire.news/og/news/2026/11/boehringer-survodutide-synchronize-cvot-aha-2026-16x9.jpg</image:loc></image:image>
  </url>
  <url>
    <loc>https://aminowire.news/news/2026/11/fda-naion-warning-glp-1-receptor-agonists/</loc>
    <news:news>
      <news:publication><news:name>Amino Wire</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-11-09T16:13:54.000Z</news:publication_date>
      <news:title>FDA adds NAION eye-risk warning to all GLP-1 labels</news:title>
    </news:news>
    <image:image><image:loc>https://aminowire.news/og/news/2026/11/fda-naion-warning-glp-1-receptor-agonists-16x9.jpg</image:loc></image:image>
  </url>
  <url>
    <loc>https://aminowire.news/news/2026/11/hims-hers-q3-2026-results/</loc>
    <news:news>
      <news:publication><news:name>Amino Wire</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-11-09T22:06:25.000Z</news:publication_date>
      <news:title>Hims Q3 revenue rose 49% as it cuts 2026 profit guide</news:title>
    </news:news>
    <image:image><image:loc>https://aminowire.news/og/news/2026/11/hims-hers-q3-2026-results-16x9.jpg</image:loc></image:image>
  </url>
  <url>
    <loc>https://aminowire.news/news/2026/11/hims-peptides-plus-november-launch/</loc>
    <news:news>
      <news:publication><news:name>Amino Wire</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-11-10T00:13:03.000Z</news:publication_date>
      <news:title>Hims says Peptides+ will launch later this month</news:title>
    </news:news>
    <image:image><image:loc>https://aminowire.news/og/news/2026/11/hims-peptides-plus-november-launch-16x9.jpg</image:loc></image:image>
  </url>
  <url>
    <loc>https://aminowire.news/news/2026/11/lilly-foundayo-orforglipron-attain-osa-phase-3/</loc>
    <news:news>
      <news:publication><news:name>Amino Wire</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-11-09T18:06:24.000Z</news:publication_date>
      <news:title>Lilly&apos;s Foundayo cuts sleep apnea events in Phase 3</news:title>
    </news:news>
    <image:image><image:loc>https://aminowire.news/og/news/2026/11/lilly-foundayo-orforglipron-attain-osa-phase-3-16x9.jpg</image:loc></image:image>
  </url>
  <url>
    <loc>https://aminowire.news/news/2026/11/merck-efinopegdutide-mash-phase-2b/</loc>
    <news:news>
      <news:publication><news:name>Amino Wire</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-11-09T22:06:25.000Z</news:publication_date>
      <news:title>Merck&apos;s efinopegdutide meets Phase 2b MASH endpoint</news:title>
    </news:news>
    <image:image><image:loc>https://aminowire.news/og/news/2026/11/merck-efinopegdutide-mash-phase-2b-16x9.jpg</image:loc></image:image>
  </url>
  <url>
    <loc>https://aminowire.news/news/2026/11/retatrutide-transcend-ckd-registry-results/</loc>
    <news:news>
      <news:publication><news:name>Amino Wire</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-11-09T14:15:50.000Z</news:publication_date>
      <news:title>Retatrutide kidney trial results posted: GFR flat, albumin down</news:title>
    </news:news>
    <image:image><image:loc>https://aminowire.news/og/news/2026/11/retatrutide-transcend-ckd-registry-results-16x9.jpg</image:loc></image:image>
  </url>
  <url>
    <loc>https://aminowire.news/news/2026/11/sandoz-owozy-semaglutide-brazil-launch/</loc>
    <news:news>
      <news:publication><news:name>Amino Wire</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-11-10T02:09:04.000Z</news:publication_date>
      <news:title>Sandoz launches Owozy semaglutide in Brazil</news:title>
    </news:news>
    <image:image><image:loc>https://aminowire.news/og/news/2026/11/sandoz-owozy-semaglutide-brazil-launch-16x9.jpg</image:loc></image:image>
  </url>
  <url>
    <loc>https://aminowire.news/news/2026/11/novo-zalfermin-cagrilintide-semaglutide-alcohol-liver-aasld-2026/</loc>
    <news:news>
      <news:publication><news:name>Amino Wire</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-11-08T22:12:49.000Z</news:publication_date>
      <news:title>Novo drugs cut fibrosis markers in alcohol-related liver disease</news:title>
    </news:news>
    <image:image><image:loc>https://aminowire.news/og/news/2026/11/novo-zalfermin-cagrilintide-semaglutide-alcohol-liver-aasld-2026-16x9.jpg</image:loc></image:image>
  </url>
  <url>
    <loc>https://aminowire.news/news/2026/11/jnj-icotyde-icotrokinra-iconic-psa-1-phase-3/</loc>
    <news:news>
      <news:publication><news:name>Amino Wire</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-11-09T12:13:46.000Z</news:publication_date>
      <news:title>J&amp;J&apos;s Icotyde meets Phase 3 goal in psoriatic arthritis</news:title>
    </news:news>
    <image:image><image:loc>https://aminowire.news/og/news/2026/11/jnj-icotyde-icotrokinra-iconic-psa-1-phase-3-16x9.jpg</image:loc></image:image>
  </url>
</urlset>
